CG Oncology (CGON) director sells 1,000 shares at $71.17
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares of Common Stock at $0.60 per share and on July 15, 2026 sold 1,000 shares at $71.17 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he held no Common Stock directly and 105,077 fully vested Director Stock Options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 1,000 shares ($71,170)
Net Sell
3 txns
Insider
POST LEONARD E
Role
Director
Sold
1,000 shs ($71K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) | 1,000 | $0.00 | -- |
| Exercise | Common Stock | 1,000 | $0.60 | $600.00 |
| Sale | Common Stock | 1,000 | $71.17 | $71K |
Holdings After Transaction:
Director Stock Option (right to buy) — 105,077 shares (Direct);
Common Stock — 1,000 shares (Direct)
Footnotes (1)
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. Fully vested
Key Figures
Shares sold: 1,000 shares
Sale price: $71.17 per share
Shares acquired via option exercise: 1,000 shares
+3 more
6 metrics
Shares sold
1,000 shares
Common Stock sold on 2026-07-15 at $71.17 per share
Sale price
$71.17 per share
Price for 1,000 Common Stock shares in a sale coded S
Shares acquired via option exercise
1,000 shares
Common Stock acquired through option exercise on 2026-07-15
Option exercise price
$0.60 per share
Exercise price for Director Stock Option converting into 1,000 Common Stock shares
Options remaining
105,077 options
Director Stock Options held after exercising 1,000 options
Option expiration date
2028-07-08
Expiration date of the reported Director Stock Option series
Key Terms
Rule 10b5-1 trading plan, Director Stock Option (right to buy), derivative security
3 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Director Stock Option (right to buy) financial
"Director Stock Option (right to buy) reported as a derivative security"
derivative security financial
"Exercise or conversion of derivative security coded as transaction type M"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did CGON director Leonard E. Post report?
Leonard E. Post reported exercising 1,000 stock options for CG Oncology Common Stock at $0.60 per share and selling 1,000 shares at $71.17 per share on July 15, 2026, leaving no direct Common Stock holdings and remaining option holdings.
What CGON stock options does Leonard E. Post still hold after this transaction?
After exercising 1,000 options, Leonard E. Post held 105,077 Director Stock Options. These options are reported as fully vested and relate to CG Oncology Common Stock, with the specific option series shown expiring on July 8, 2028.
At what price were CGON options exercised in Leonard E. Post’s recent transaction?
The options were exercised at an exercise price of $0.60 per share for 1,000 shares of CG Oncology Common Stock. The exercise reduced the option position by 1,000 and simultaneously created 1,000 shares that were then sold the same day.
Does Leonard E. Post hold any CGON Common Stock after the reported transactions?
No. Following the reported sale of 1,000 shares, Leonard E. Post’s direct holdings of CG Oncology Common Stock are reported as 0 shares. His remaining exposure comes from 105,077 outstanding stock options rather than direct share ownership.